First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC
Phase III Study Being Initiated For Two-Drug Regimen
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.
